How Trenbolone Acetate Affects Potassium

Trenbolone is a 19-nortestosterone derivative. Its structural class binds the mineralocorticoid receptor as a full agonist, where progesterone antagonises it (Funder and Adam, 1981, PMID 6263590). That means trenbolone signals through the same receptor aldosterone uses, driving sodium retention and potassium loss via the renal collecting duct.

Two mechanisms shape what shows on bloodwork:

1. Direct MR agonism: Trenbolone activates ENaC and ROMK channels in the principal cells of the collecting duct, increasing sodium reabsorption and potassium secretion into the urine. This is the same pathway aldosterone uses, just driven by an exogenous androgen.
2. RAAS upregulation: AAS broadly upregulate the cardiac and systemic renin-angiotensin system (Rocha et al., 2007, PMID 17906098). Aldosterone rises alongside angiotensin II, compounding the mineralocorticoid signal.

Net effect on potassium: a mild downward drift during cycle, often within the normal range but with reduced reserve. The clinical relevance shows when an ARB or ACE inhibitor is added (or removed) for blood pressure control. Both drug classes raise potassium. Adding telmisartan or lisinopril on top of trenbolone's mineralocorticoid suppression can produce paradoxical hyperkalaemia at dose changes, because the MR-driven potassium loss masks the underlying ARB-induced retention until trenbolone is stopped or tapered.

On trenbolone monotherapy (50-100 mg every other day):

• Serum potassium typically drifts down 0.1 to 0.3 mmol/L from baseline
• Usually stays within the normal range (3.5 to 5.0 mmol/L)
• Sodium often rises slightly, water retention is the visible symptom (sub-cutaneous bloat, slight BP rise)

Trenbolone plus ARB or ACE inhibitor:

• During concurrent use: potassium can sit deceptively in mid-range (4.5 to 5.0)
• When trenbolone is stopped abruptly while the ARB continues: potassium can rebound rapidly into the 5.5 to 6.0 range within one to two weeks as the MR-driven potassium loss disappears but the ARB's potassium-retaining effect persists
• This is the under-appreciated risk: a user comes off cycle, keeps the BP medication, and develops symptomatic hyperkalaemia

Stacked with spironolactone (rare but real):

• Both drugs target the MR with opposing effects
• Spironolactone wins at typical doses (50 to 100 mg)
• Potassium can rise above 5.5 quickly, especially with concurrent ARB use

Baseline before starting trenbolone: Pull a basic metabolic panel including potassium, sodium, creatinine, and eGFR. Document baseline blood pressure too, since trenbolone's MR activity is the dominant BP driver in many users.

During cycle:

• Recheck potassium at week 4 of trenbolone use
• If on concurrent ARB or ACE inhibitor, recheck within two weeks of any dose change to either drug
• Pull potassium any time you change diet substantially (electrolyte powders, low-carb cuts, increased leafy greens)

Post-cycle / on trenbolone taper:

• This is the highest-risk window for hyperkalaemia if BP medication continues
• Pull potassium at 1 and 4 weeks after stopping trenbolone if telmisartan or lisinopril continues
• Threshold for action: potassium 5.5 or higher means reduce ARB dose by half and recheck in one to two weeks (Bakris and Weir, 2000, PMID 10724055); 6.0 or higher means hold the ARB

On cycle:

• Keep dietary potassium consistent. Don't load up on potatoes, bananas, and electrolyte powders without monitoring labs
• Avoid combining trenbolone with spironolactone unless under physician supervision; both target the MR
• If using NSAIDs for joint pain, that's a third potassium-raising influence (NSAIDs blunt prostaglandin-mediated potassium secretion); combine cautiously

Coming off cycle:

• Don't stop trenbolone abruptly while continuing an ARB at full dose; consider tapering the trenbolone or stepping the ARB dose down at the same time
• If you've been on trenbolone plus telmisartan for several months, pull a potassium check before and two weeks after coming off

Switching antihypertensive class: If hyperkalaemia is a recurring problem, nebivolol and amlodipine are potassium-neutral alternatives. Switching from telmisartan to nebivolol plus amlodipine is the cleanest path when trenbolone keeps tipping the balance.